AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04660240 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Abluminus Sirolimus Eluting Stent System (ASES)
Description: The procedure will be conducted in accordance with the CE mark instructions for use for the ASES.~The need or not for postdilation in any segment of the stent will be at the discretion of the operator, seeking its adequate expansion and apposition. To consider PCI to be successful, residual stenosis must be less than or equal to 30% by angiography at the end of the procedure, including the absence of coronary dissection that compromises distal flow or a hemodynamically significant pressure gradient across the lesion.
Study NCT04660240 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Orsiro Sirolimus Eluting Coronary Stent System (OSES)
Description: The procedure will be conducted in accordance with the CE mark instructions for use for the OSES.~The need or not for postdilation in any segment of the stent will be at the discretion of the operator, seeking its adequate expansion and apposition. To consider PCI to be successful, residual stenosis must be less than or equal to 30% by angiography at the end of the procedure, including the absence of coronary dissection that compromises distal flow or a hemodynamically significant pressure gradient across the lesion.
Study NCT00909389 — intervention group
Intervention type: DRUG
Intervention: Vytorin (R) (Ezetimibe + Simvastatin)
Description: Vytorin (R) (Ezetimibe + Simvastatin) 1 tablet once daily to be taken by mouth in the evening for 28 days
Study NCT01542151 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Time of labor induction
Description: Assigned time of labor induction - morning or evening
Study NCT01542151 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Time of labor induction
Description: Assigned time of labor induction - morning or evening
Study NCT00270907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CT-2103
Description: 135 mg/m\^2 IV on Day 1.
Study NCT00270907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000 mg/m\^2 IV on Day 1 and 8.
Study NCT03645707 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CAR Training and Psychoeducational Sessions
Description: Participation in the CAR Training Program, a 1-day training program developed by the J\&J Human Performance Institute (HPI). The CAR Training Program uses a holistic approach that focuses on moving between stress and strategic recovery to help build resilience and enable higher performance.~Participants will attend eight weekly follow-up psychoeducational group sessions facilitated by a licensed mental health counselor that will meet for 90 minutes. The themes of these sessions will be RISE - Resilience, Insight, Self-Compassion, and Empowerment. Due to limited time and flexibility in sessions, participants will practice skills through optional homework activities to facilitate learning between sessions.
Study NCT02040441 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Spironolactone
Study NCT02040441 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02040441 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Standard care
Description: Standard diabetes care
Study NCT02040441 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard care
Description: Standard diabetes care
Study NCT02040441 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Standard diabetes care
Study NCT03155516 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Good pain management (GPM) procedure
Description: In the GPM ward, a close pain assessment will be carried within 1 hour after admission. After the assessment, patient will be given analgesic treatment as needed, by acceptable route, frequency and dosage. A good titration is required in GPM ward. Patient will be close monitor his/her pain level regarding pain score. In opioid use, when patient complains patient level ≥ 4, low dose strong opioids will be introduced in patient suffering with moderate pain.~Compare with current practice, GPM ward will perform pain assessment with higher frequency for adjusting of analgesic medications if required.
Study NCT03155516 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Current practice procedure
Description: Current practice clinical procedure for pain management
Study NCT01860352 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Fish OIl
Study NCT02180737 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmeditomedine
Study NCT02645331 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Remind-to-move
Study NCT02645331 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Modified constraint induced movement therapy
Study NCT02645331 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Conventional rehabilitation
Study NCT06321679 — intervention group
Intervention type: PROCEDURE
Intervention: Imaging evaluation
Description: each patient will undergo imaging with CT, BS and WB-MRI at each study timepoint
Study NCT02208739 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nonsurgical periodontal therapy
Description: All patients were instructed in oral hygiene methods using a soft bristled toothbrush, a compact-tuft toothbrush, interdental brushes and dental floss utilizing the modified Bass technique. Full mouth debridement, which consisted of scaling and root planing, was done in a single visit for all subjects using an ultrasonic scaler and gracey curettes. Additionally, all patients were given a 0.12% Chlorhexidine mouthrinse (Hexipro®). They were instructed to rinse three times a day using 15ml each time for a period of 14 days commencing immediately after completion of full mouth debridement. Thereafter at each recall visit, all participants were re-motivated and professional prophylaxis was performed.
Study NCT02208739 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Nonsurgical periodontal therapy
Description: All patients were instructed in oral hygiene methods using a soft bristled toothbrush, a compact-tuft toothbrush, interdental brushes and dental floss utilizing the modified Bass technique. Full mouth debridement, which consisted of scaling and root planing, was done in a single visit for all subjects using an ultrasonic scaler and gracey curettes. Additionally, all patients were given a 0.12% Chlorhexidine mouthrinse (Hexipro®). They were instructed to rinse three times a day using 15ml each time for a period of 14 days commencing immediately after completion of full mouth debridement. Thereafter at each recall visit, all participants were re-motivated and professional prophylaxis was performed.
Study NCT02208739 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Oral hygiene instructions
Description: All patients were instructed in oral hygiene methods using a soft bristled toothbrush, a compact-tuft toothbrush, interdental brushes and dental floss utilizing the modified Bass technique.
Study NCT00598572 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferoxamine Mesylate
Description: Various dose-regimens ranging from 7 mg/kg to 125 mg/kg (with a maximum allowable total daily dose of 6000 mg at any of the tested dose tiers, regardless of patient's weight), administered daily by IV infusion for three consecutive days.
Study NCT02184689 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fexinidazole
Study NCT04471012 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Individual counselling program
Description: An individual counseling program that was based on TM and included motivational interview techniques was given to the experimental group which involved general information about the importance of weight control, healthy diet, and exercise.~Benefits of Healthy Diet and Physical Activity in PCOS Training Booklet was given during their first counseling session.
Study NCT02733588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-Pump™ (glucagon infusion)
Description: 0.15 or 0.3 mg G-Pump™ (glucagon infusion) administered from OmniPod® pump
Study NCT02999854 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ATIR101
Description: ATIR101 is a T-lymphocyte enriched leukocyte preparation depleted ex vivo of host alloreactive T-cells using photodynamic treatment; single dose of 2×10E6 viable T-cells/kg body weight between 28 and 32 days after the HSCT (intravenous infusion)
Study NCT02999854 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: High dose post-transplant cyclophosphamide 50 mg/kg/day at 3 and 4/5 days after the HSCT (powder for intravenous infusion)
Study NCT00622089 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DIO-902
Description: 150mg DIO-902 + 10mg atorvastatin
Study NCT00622089 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DIO-902
Description: 300mg dose once per day for 24 weeks
Study NCT00622089 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DIO-902
Description: 450mg dose once per day for 24 weeks
Study NCT05878756 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Functional Strength Training
Description: In addition to conventional therapy, experimental group was also given functional strength training program. Functional strength training was given as home program consisting of ten tasks.The ten tasks were STS, one leg standing, weight shifting(from one side of body to other), step-ups, lateral step-ups, squatting against wall, picking an object from standing position, walking forward, walking backward and kicking the ball.
Study NCT05878756 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional Strength Training
Description: In addition to conventional therapy, experimental group was also given functional strength training program. Functional strength training was given as home program consisting of ten tasks.The ten tasks were STS, one leg standing, weight shifting(from one side of body to other), step-ups, lateral step-ups, squatting against wall, picking an object from standing position, walking forward, walking backward and kicking the ball.
Study NCT00929188 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-42160443
Description: Type=1, unit=mg, number=10, form=solution for injection , route=subcutaneous use. SC injection (10mg/ml) once every 4 weeks for up to 52 weeks
Study NCT00929188 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Form=solution for injection, route=subcutaneous use. SC injection (0.9 mL matching placebo) once on Day 1
Study NCT01632228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Participants will receive bevacizumab 15 milligrams per kilogram (mg/kg) IV infusion every 3 weeks until disease progression, unacceptable toxicity, participants or physician decision to discontinue, or death.
Study NCT01632228 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Participants will receive bevacizumab 15 milligrams per kilogram (mg/kg) IV infusion every 3 weeks until disease progression, unacceptable toxicity, participants or physician decision to discontinue, or death.
Study NCT01632228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Onartuzumab
Description: Participants will receive onartuzumab 15 mg/kg IV infusion every 3 weeks until disease progression, unacceptable toxicity, participants or physician decision to discontinue, or death.
Study NCT01632228 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo matched with onartuzumab until disease progression, unacceptable toxicity, participants or physician decision to discontinue, or death.
Study NCT00359333 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine , Docetaxel
Description: Gemcitabine 800 mg/m2 IV over 80 minutes on day 1 and day 8, and Docetaxel 60 mg/m2 IV over 60 minutes on day 1 of a 21-day cycle
Study NCT03488888 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Normal Saline 0,9%
Description: Ultrasound-guided PEC II block with 30 mL of Normal Saline 0,9%
Study NCT03488888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: Ultrasound-Guided PEC block with 30 mL of 0.25% bupivacaine solution
Study NCT02982317 — intervention group
Intervention type: PROCEDURE
Intervention: Manual palpation identification lumbar spine
Study NCT02982317 — intervention group
Intervention type: PROCEDURE
Intervention: Automated ultrasound technology identification
Description: This technology involves a standard ultrasound machine and curvilinear probe- what is novel is the software which will be connected to the ultrasound machine
Study NCT02982317 — intervention group
Intervention type: PROCEDURE
Intervention: Lumbar level identification gold standard ultrasound
Study NCT04894643 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Proton Ions
Description: According to the radiation plan (between 50.4 and a maximum of 60.2 Gy) after Chemotherapy with Nab-PACLitaxel (Abraxane®) + Gemcitabine and concomitant to Capecitabine.
Study NCT04894643 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Nab-PACLitaxel
Description: Chemotherapy will be delivered upfront for three cycles (week 2-4, week 6-8 and week 10-12) with combined Nab-PACLitaxel (Abraxane®) and Gemcitabine Therapy.~It will be administered as intra venous infusion over 30 minutes.
Study NCT02445352 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (for Rosuvastatin 5mg and DP-R207 5/10mg)
Study NCT04894643 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Gemcitabine
Description: Chemotherapy will be delivered upfront for three cycles (week 2-4, week 6-8 and week 10-12) with combined Nab-PACLitaxel (Abraxane®) and Gemcitabine Therapy.~Gemcitabine will also be administered as intra venous infusion over 30 minutes immediately after Nab-PACLitaxel.
Study NCT04894643 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Capecitabine
Description: Concomitant to proton-radiotherapy (on the same days, within week 14-19)
Study NCT04894643 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Surgical resection of the pancreas (when feasible)
Description: Pre surgical re-evaluation will be performed at week 21 after enrollment. Patients fulfilling surgery-entry criteria, which consist of no distant metastasis, no massive ascites, no massive pleural effusion, no serious infection, no serious, unresolved chemoradiotherapy related, adverse events and adequate organ system function, will undergo surgery on week 22 (± 1 week). This should be performed via laparotomy.
Study NCT00991328 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SctO2 < 60 %.
Description: The following intervention protocol will be applied when SctO2 level falls below 60 %. First, the patients head position will be checked for suitable position and the face will be observed for plethora. Then the efforts will be made to maintain PaCO2 between 40-50 mmHg and MAP of 60 - 80 mm Hg. Cardiac index will be maintained between 2.0 - 2.5 L/min/m2. The hematocrit should be more than 20 %. The red blood cells or hemoconcentration will be used for this purpose.
Study NCT00442832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-1792
Description: TD-1792 2 mg/kg/day IV
Study NCT00442832 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin
Description: Vancomycin 1 Gm IV q 12 hrs
Study NCT01571908 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium perfusion
Description: The patient receives during 15 minutes a perfusion of 60mg/kg of Magnesium sulphate before induction of anaesthesia.
Study NCT01571908 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium
Description: Immediately after anaesthesia induction and loss of consciousness 0,6 mg/kg of rocuronium will be injected
Study NCT01571908 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo perfusion
Description: The patient receives during 15 minutes a perfusion of 1 ml/kg of saline before induction of anaesthesia
Study NCT01571908 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Succinylcholine
Description: Immediately after anaesthesia induction at loss of consciousness 1 mg/kg of succinylcholine will be injected
Study NCT03040414 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MedtronicMinimed 670G 3.0 hybrid closed loop system
Description: The components of the intervention are the insulin pump with insulin delivery algorithm (PID).
Study NCT03040414 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medtronic Minimed 670G 4.0 AHCL with Guardian Sensor (3) continuous glucose monitoring sensor.
Description: The components of the intervention are the insulin pump with insulin delivery algorithm (PID + Fuzzy Logic) and Guardian Sensor (3).
Study NCT02337972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: povidone-iodine 4%
Description: Prior to each injection and before the use of povidone-iodine drops, a conjunctival culture will be taken
Study NCT01498627 — intervention group
Intervention type: BIOLOGICAL
Intervention: Cervarix
Description: 3 doses over a period of 6 months (Month 0 and ideally Month 1 and Month 6, with 1 month minimum between any two doses).
Study NCT01498627 — intervention group
Intervention type: OTHER
Intervention: Data collection
Description: PGRx information system
Study NCT02445352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (for Rosuvastatin 10mg and DP-R207 10/10mg)
Study NCT00771732 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: light therapy
Description: 6 minute light therapy
Study NCT00771732 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: light therapy
Description: combination of wavelengths
Study NCT01740479 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Complete Revascularization Strategy
Description: Staged PCI using second generation drug eluting stents (Promus Element Plus drug-eluting stent or newer version in this series is strongly recommended) of all suitable non-culprit lesions plus optimal medical therapy.
Study NCT02931604 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SinuSafe Medical Device for Maxillary Sinus
Description: Sinus lavage via the natural sinus ostium, without ostial dilation.
Study NCT02445352 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (for Rosuvastatin 10mg and DP-R207 10/10mg)
Study NCT02157792 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M6620
Study NCT02157792 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Study NCT02157792 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Study NCT03887793 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VACs
Description: The VACs (Vaccinate Adolescents against Cancer) model for HPV vaccine quality improvement is a strategy developed by the American Cancer Society to improve HPV vaccination coverage in large integrated health care delivery systems. It includes the development of a quality improvement (QI) action plan, the formation of a QI team of health care providers, education for the QI team about HPV-related disease burden and vaccine efficacy, HPV vaccine coverage assessments at several time points that are shared with individual clinics within the health are system, and the adoption of specific QI strategies by participating clinics in the health care system.
Study NCT02794597 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SHINE intervention group
Description: Includes all substance treatment services as well as the brief peer-led behavioral intervention focused on contraceptives, reproductive needs, and motivational interviewing: Sexual Health Initiative for Navigation and Empowerment (SHINE).
Study NCT01316315 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active
Description: A 5 mg single dose given intravenously via syringe pump over 1 minute.
Study NCT01316315 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Same as active
Study NCT02195661 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin
Study NCT02195661 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Chloral Hydrate
Study NCT02445352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (for Rosuvastatin 20mg and DP-R207 20/10mg)
Study NCT02445352 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (for Rosuvastatin 20mg and DP-R207 20/10mg)
Study NCT03220594 — intervention group
Intervention type: PROCEDURE
Intervention: hypogastric artery ligation
Description: hypogastric artery ligation is the ligation of the internal iliac artery to stop bleeding related to obstetrics obstetric hemorrhage Hysterectomy is the removal of the uterus if bleeding can't stop by hypogastric artery ligation
Study NCT04835935 — intervention group
Intervention type: OTHER
Intervention: microbiome pattern
Description: microbiome pattern in neonatal period
Study NCT02157792 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Study NCT02157792 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Study NCT02157792 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Study NCT00263640 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Acaroid
Description: The drug tested in this study (aluminium hydroxide-adsorbed house dust mite (D. pteronyssinus) allergoid preparation) was given as a subcutaneous injections of increasing doses.
Study NCT00263640 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo was given the same way as a subcutaneous (just under the skin) injection. Patients were treated according the same dosing schedule of active group. Children received lifestyle counselling.